|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.M204V+rt.L180M;rt.M204I+rt.L180M;rt.M204V+rt.L180M+rt.V173L |
|
Relevant Drug
|
lamivudine (LAM);tenofovir (TDF);adefovir (ADV) |
Literature Information
|
PubMed PMID
|
21871497
|
|
Published Year
|
2011 |
|
Journal
|
Antiviral research |
|
Title
|
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. |
|
Author
|
Billioud G,Pichoud C,Puerstinger G,Neyts J,Zoulim F |
|
Evidence
|
HepG2 stable cell line permanently expressing wild type (WT) HBV or the main HBV mutants resistant to lamivudine and/or adefovir (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I, rtL180M+rtM204I, rtN236T, rtA181V, rtA181V+rtN236T, rtA181T, rtA181T+rtN236T) were treated with AT-61, AT-130 or BAY-41 4109.
|
|
|
HBV Mutation Detail Information